A phase III study of comparing FOLFOX plus /-bevacizumab with FOLFOX plus /-bevacizumab plus high-dose intravenous vitamin C as first-line therapy in patients with advanced colorectal cancer.

被引：0
|
作者：
Wang, Feng
Xiao, Jian
Zhang, Yan-Qiao
Yuan, Xianglin
Fang, Weijia
Wang, Wei
Hu, Xiaohua
Zhuang, Zhixiang
Zhou, Fuxiang
Ying, Jieer
Yuan, Ying
Guo, Zeng-qing
Wu, XiangYuan
Zou, Qing-Feng
He, Ming-ming
Guo, Ying
Chen, Shuang-Zhen
Xu, Rui-hua
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Dept Med Oncol, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Affiliated Hosp 6, Guangzhou, Peoples R China
[3] Harbin Tumor Hosp, Dept Gastrointestinal Med Oncol, Harbin, Peoples R China
[4] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Wuhan, Peoples R China
[5] First Affiliated Hosp Zhejiang Prov, Hangzhou, Peoples R China
[6] First Peoples Hosp Foshan, Guangzhou, Foshan, Peoples R China
[7] Guangxi Med Univ, Affiliated Canc Hosp, Nanning, Guangxi, Peoples R China
[8] SooChow Univ, Affiliated Hosp 2, Dept Med Oncol, Suzhou, Peoples R China
[9] Wuhan Univ, Zhongnan Hosp, Hubei Canc Clin Study Ctr, Wuhan, Peoples R China
[10] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou, Peoples R China
[11] Fujian Med Univ, Canc Hosp, Canc Bioimmunotherapy Ctr, Fuzhou, Peoples R China
[12] Fujian Canc Hosp, Fuzhou, Peoples R China
[13] Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou, Peoples R China
[14] Guangzhou Med Univ, Canc Ctr, Guangzhou, Peoples R China
[15] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4115
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A randomized, open-label, multicenter, phase III study of high-dose vitamin C plus FOLFOX plus /- bevacizumab versus FOLFOX plus /- bevacizumab as first-line treatment in patients with unresectable metastatic colorectal cancer
    Wang, F.
    Xiao, J.
    Zhang, Y.
    Yuan, X.
    He, M.
    Fang, W.
    Zhang, Y.
    Wang, W.
    Hu, X.
    Ma, Z.
    Yao, Y.
    Zhuang, Z.
    Zhou, F.
    Ying, J.
    Yuan, Y.
    Zou, Q.
    Guo, Z.
    Wu, X.
    Jin, Y.
    Mai, Z.
    Guo, Y.
    Xu, R.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S364 - S364
  • [2] Olaparib plus /- bevacizumab versus bevacizumab plus fluorouracil in patients with unresectable or metastatic colorectal cancer not progressing on first-line FOLFOX plus bevacizumab: Phase III LYNK-003 study.
    Mayo, Carlos Alberto
    Gurary, Ellen B.
    Marinello, Patricia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [3] Bevacizumab plus FOLFOX7 as first line treatment in patients with advanced colorectal cancer
    Oukkal, M.
    Kara, F.
    Difi, S.
    Bouzidi, D.
    Bentabak, K.
    Graba, A.
    Smail, N.
    Kaci, N. Ait
    Ahmed, R. Baba
    Bouzid, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] FOLFOX plus cetuximab in first-line therapy of advanced colorectal cancer
    Ehrenberg, Roland
    Halama, Niels
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6
  • [5] PHASE 3 STUDY OF OLAPARIB ± BEVACIZUMAB VERSUS BEVACIZUMAB plus FLUOROURACIL IN PATIENTS WITH UNRESECTABLE OR METASTATIC COLORECTAL CANCER NOT PROGRESSING ON FIRST-LINE FOLFOX plus BEVACIZUMAB (LYNK-003)
    Mayo, Carlos
    Gurary, Ellen B.
    Marinello, Patricia
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A201 - A201
  • [6] A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ? Bevacizumab versus FOLFOX ? Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
    Wang, Feng
    He, Ming -Ming
    Xiao, Jian
    Zhang, Yan-Qiao
    Yuan, Xiang-Lin
    Fang, Wei-Jia
    Zhang, Yan
    Wang, Wei
    Hu, Xiao-Hua
    Ma, Zhi-Gang
    Yao, Yi-Chen
    Zhuang, Zhi-Xiang
    Zhou, Fu-Xiang
    Ying, Jie-Er
    Yuan, Ying
    Zou, Qing-Feng
    Guo, Zeng-Qing
    Wu, Xiang-Yuan
    Jin, Ying
    Mai, Zong-Jiong
    Wang, Zhi-Qiang
    Qiu, Hong
    Guo, Ying
    Shi, Si -Mei
    Chen, Shuang-Zhen
    Luo, Hui-Yan
    Zhang, Dong-Sheng
    Wang, Feng-Hua
    Li, Yu-Hong
    Xu, Rui-Hua
    [J]. CLINICAL CANCER RESEARCH, 2022, 28 (19) : 4232 - 4239
  • [7] Stop and Go FOLFOX plus Bevacizumab Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer
    Vaidyanathan, Gayatri
    Groman, Adrienne
    Wilding, Gregory
    Fakih, Marwan G.
    [J]. ONCOLOGY, 2010, 79 (1-2) : 67 - 71
  • [8] Phase Ib study of drozitumab combined with first-line FOLFOX plus bevacizumab (BV) in patients (pts) with metastatic colorectal cancer (mCRC).
    Lima, C. S. Rocha
    Baranda, J. C.
    Wallmark, J.
    Choi, Y.
    Royer-Joo, S.
    Portera, C. C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [9] Phase III Trial of FOLFOX plus Bevacizumab or Cediranib (AZD2171) as First-Line Treatment of Patients with Metastatic Colorectal Cancer: HORIZON III
    Robertson, Jane D.
    Botwood, Nick A.
    Rothenberg, Mace L.
    Schmoll, Hans-Joachim
    [J]. CLINICAL COLORECTAL CANCER, 2009, 8 (01) : 59 - 60
  • [10] Predicting benefit from FOLFOXIRI plus bevacizumab versus FOLFOX/FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer
    Bond, M. J. G.
    van Smeden, M.
    Degeling, K.
    Cremolini, C.
    Schmoll, H. J. E-V.
    Rossini, D.
    Ibach, S.
    Koopman, M.
    Punt, C. J. A.
    May, A. M.
    Kwakman, J. J.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S438 - S438
12345